^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    EGFR (Epidermal growth factor receptor)

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    1m
    Adjuvant targeted therapy in high-risk stage IB epidermal growth factor receptor-mutant lung cancer: Role of ground-glass opacity components. (PubMed, JTCVS Open)
    Adjuvant targeted therapy did not improve long-term survival in stage IB EGFR-mutant NSCLC with high-risk features, although it prolonged DFS in pure-solid tumors. A de-escalation strategy may be considered for postoperative management, particularly in part-solid tumors.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    1m
    PLAG1-Driven Lipoblastomatosis: Diagnostic Insights from a Case Report and Literature Review. (PubMed, Turk Patoloji Derg)
    Identification of PLAG1 rearrangement is crucial for confirming the diagnosis. With the growing number of molecularly defined soft-tissue tumours of diagnostic and prognostic significance, incorporating molecular analysis is essential in the evaluation of soft-tissue lesions.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • EWSR1 (EWS RNA Binding Protein 1) • CD34 (CD34 molecule) • DDIT3 (DNA-damage-inducible transcript 3) • PLAG1 (PLAG1 Zinc Finger)
    |
    EGFR exon 20 insertion • EGFR exon 20 mutation
    1m
    Advances and challenges in CAR-T cell therapy for breast cancer: from molecular design to clinical application. (PubMed, Cancer Causes Control)
    Furthermore, the article explores the primary targets of CAR-T cell therapy in the clinical treatment of breast cancer, such as HER2, EGFR, and MUC1, and analyzes the potential and limitations of these targets in therapy. In conclusion, the review outlines significant hurdles in CAR-T cell therapy for breast cancer, such as tumor diversity, the inhibitory tumor milieu, unintended targeting, and cytokine storm, offering strategic solutions to mitigate these obstacles.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • MUC1 (Mucin 1)
    1m
    Spatial Transcriptomic Dissection of the Cellular and Molecular Architecture of Fear Memory and its Association with Memory Function. (PubMed, Curr Neuropharmacol)
    This study provides a spatially resolved characterization of cellular composition, intercellular communication, and molecular regulation associated with FM. The findings generate new hypotheses regarding the relationship between emotional regulation and memory function, particularly the possibility that FM formation and consolidation compromise general memory processes. Collectively, these results offer new insights into the cellular and molecular neurobiology of FM.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • NCAM1 (Neural cell adhesion molecule 1)
    1m
    Recent Advancements in the Development of Heterocyclic Scaffolds as Potential Anti-cancer Agents Targeting EGFR and VEGFR-2. (PubMed, Mini Rev Med Chem)
    This review article provides information on the specific compounds found to have the most potent activity against various cancer cell lines evaluated. Therefore, further research on these novel compounds offers substantial prospects for developing potential therapeutic candidates, thereby enhancing cancer treatment.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KDR (Kinase insert domain receptor)
    1m
    An Observational Study of Afatinib 30 mg Daily in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Common EGFR Mutations Treated With Afatinib. (PubMed, Thorac Cancer)
    Afatinib 30 mg daily was well tolerated and demonstrated encouraging efficacy, with a 6-month PFS of 93.2%, suggesting outcomes comparable to standard dosing.
    Observational data • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Gilotrif (afatinib)
    1m
    MET Dependence Oversteps EGFR Dependence via Balancing Dimerization of the Receptor Tyrosine Kinases in Osimertinib-Resistant MET-Amplified, EGFR-Mutated Non-Small Cell Lung Cancer. (PubMed, Thorac Cancer)
    MET amplification alters the balance of EGFR/MET/ERBB3 dimerization, leading to a shift in signaling dependence from EGFR to MET. These findings provide insight into therapeutic strategies for EGFR-mutated NSCLC.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    EGFR mutation • MET amplification • MET overexpression • MET mutation
    |
    Tagrisso (osimertinib) • Orpathys (savolitinib)
    1m
    NIMBLE-CRC: NeoImmunoModulation Before Leveraging Excision in Colorectal Rectal Cancer (clinicaltrials.gov)
    P2, N=26, Not yet recruiting, Northwell Health
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    Zynyz (retifanlimab-dlwr) • zanzalintinib (XL092)
    1m
    Modeling a hypoxia-integrated glioblastoma microenvironment to mimic tumor heterogeneity and chemoresistance. (PubMed, Biomater Sci)
    Drug testing with temozolomide (TMZ) demonstrated reduced sensitivity under hypoxic conditions, shown by a 56% increase in IC50, reflecting clinically relevant therapy resistance. These findings show the ability of the model to mimic key properties of the GBM microenvironment at both phenotypic and molecular levels and offer a physiologically relevant platform to study GBM biology and evaluate therapeutic responses.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • MMP2 (Matrix metallopeptidase 2) • SOX2 • TGFB1 (Transforming Growth Factor Beta 1)
    |
    temozolomide
    1m
    Isofraxidin ameliorates CCl4-induced liver fibrosis in mice by inhibiting the NF-κB pathway. (PubMed, Histol Histopathol)
    IF effectively alleviated CCl4-induced liver fibrosis in mice by modulating key targets (AkT, Src, EGFR, HSP90AA1, GSK3B, and MAOB) and the NF-κB signaling pathway.
    Preclinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta) • NFKBIA (NFKB Inhibitor Alpha 2) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
    1m
    SpyCatcher-Engineered Ferritin Nanocages Enable Dual-Receptor Targeting for Enhanced Glioma Therapy. (PubMed, Bioconjug Chem)
    Doxorubicin (DOX) was efficiently encapsulated via temperature-controlled loading to obtain DOX@FTn-EGFRAfb with high protein recovery, pH-responsive drug release, and strong stability...In an orthotopic U87 glioma mouse model, DOX@FTn-EGFRAfb significantly inhibited tumor growth and prolonged survival without obvious systemic toxicity. This work presents a versatile protein-engineering strategy for dual-targeted glioblastoma drug delivery.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • TFRC
    |
    EGFR positive
    |
    doxorubicin hydrochloride
    1m
    A network pharmacology-based approach and molecular docking study to explore the therapeutic potential of a nutraceutical formula (Vernolac) in the treatment of cancer. (PubMed, PLoS One)
    Collectively, network analysis suggests that phytochemicals in Vernolac may exert anticancer effects through multiple cancer-related pathways, including those associated with apoptosis, immune modulation, oxidative stress, inflammation, and cell proliferation. Furthermore, the identified targets and enriched pathways suggest a potential role in modulating drug resistance and treatment response, providing a computational basis for its application as an adjunct to conventional cancer therapies and warranting further investigation in preclinical and clinical settings.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • BCL2 (B-cell CLL/lymphoma 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • IL6 (Interleukin 6) • CDK4 (Cyclin-dependent kinase 4) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CASP3 (Caspase 3) • GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1) • HSP90AB1 (Heat Shock Protein 90 Alpha Family Class B Member 1)